LAVA Therapeutics NV
NASDAQ:LVTX

Watchlist Manager
LAVA Therapeutics NV Logo
LAVA Therapeutics NV
NASDAQ:LVTX
Watchlist
Price: 0.9838 USD -9.74% Market Closed
Market Cap: 25.9m USD
Have any thoughts about
LAVA Therapeutics NV?
Write Note

LAVA Therapeutics NV
Free Cash Flow

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

LAVA Therapeutics NV
Free Cash Flow Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Free Cash Flow CAGR 3Y CAGR 5Y CAGR 10Y
LAVA Therapeutics NV
NASDAQ:LVTX
Free Cash Flow
-$39.7m
CAGR 3-Years
-59%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Pharming Group NV
AEX:PHARM
Free Cash Flow
-$540k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
28%
ProQR Therapeutics NV
NASDAQ:PRQR
Free Cash Flow
-€34.3m
CAGR 3-Years
7%
CAGR 5-Years
4%
CAGR 10-Years
N/A
Uniqure NV
NASDAQ:QURE
Free Cash Flow
-$184.8m
CAGR 3-Years
N/A
CAGR 5-Years
-14%
CAGR 10-Years
-13%
argenx SE
XBRU:ARGX
Free Cash Flow
-$325.2m
CAGR 3-Years
18%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Merus NV
NASDAQ:MRUS
Free Cash Flow
-$157.3m
CAGR 3-Years
-43%
CAGR 5-Years
-22%
CAGR 10-Years
N/A
No Stocks Found

LAVA Therapeutics NV
Glance View

Market Cap
25.9m USD
Industry
Biotechnology

LAVA Therapeutics NV operates as a biotechnology company, which develops immune oncology biopharmaceutical products. The company is headquartered in Utrecht, Utrecht and currently employs 55 full-time employees. The firm focuses of developing next generation Vdelta T cell engaging bispecific antibodies to fight cancer.

LVTX Intrinsic Value
2.1828 USD
Undervaluation 55%
Intrinsic Value
Price

See Also

What is LAVA Therapeutics NV's Free Cash Flow?
Free Cash Flow
-39.7m USD

Based on the financial report for Dec 31, 2023, LAVA Therapeutics NV's Free Cash Flow amounts to -39.7m USD.

What is LAVA Therapeutics NV's Free Cash Flow growth rate?
Free Cash Flow CAGR 3Y
-59%

The average annual Free Cash Flow growth rates for LAVA Therapeutics NV have been -59% over the past three years .

Back to Top